Lexgenleucel-T

N/A

Report date: 2024/09/14 20:00:06

Base Information

Drug NameLexgenleucel-T

Drug Alias NameAnti-HIV gene therapyVRX-496

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionHIV replication inhibitors

TargetsRibonucleic Acid

Therapy Area/IndicationsHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesVirxsys Corporation

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesVirxsys Corporation University Of Pennsylvania

Active IndicationsN/A

Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A